Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients

Ellis, Katrina L.; Cameron, Vicky A.; Troughton, Richard W.; Frampton, Christopher M.; Ellmers, Leigh J.; Richards, A. Mark

doi:10.1093/eurjhf/hft078

Cited by 158 publications

(137 citation statements)

References 39 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The authors further successfully developed a score from these miRNAs that can discriminate HF patients from healthy controls and found a significant association between this miRNA score and several established HF parameters such as NT-proBNP, a wide QRS complex, and LV dilatation [93]. Another clinically important study analyzed plasma of 44 HF patients compared to 32 chronic obstructive pulmonary disease (COPD) patients, 59 patients with breathlessness for other diagnoses, and 15 healthy controls with respect to miRNA levels [36]. The authors performed regression and ROC analyses and reported seven miRNAs associated with HF diagnosis (miR-103, AUC 0.642; miR-142-3p, AUC 0.668; miR-199a-3p, AUC 0.668; miR-23a, AUC 0.637; miR-27b, AUC 0.642; miR-324-5p, AUC 0.621; miR-342-3p, AUC 0.644) [36].…”

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

“…Another clinically important study analyzed plasma of 44 HF patients compared to 32 chronic obstructive pulmonary disease (COPD) patients, 59 patients with breathlessness for other diagnoses, and 15 healthy controls with respect to miRNA levels [36]. The authors performed regression and ROC analyses and reported seven miRNAs associated with HF diagnosis (miR-103, AUC 0.642; miR-142-3p, AUC 0.668; miR-199a-3p, AUC 0.668; miR-23a, AUC 0.637; miR-27b, AUC 0.642; miR-324-5p, AUC 0.621; miR-342-3p, AUC 0.644) [36]. Interestingly, from a clinical point of view, plasma levels of four of these miRNAs were suitable to distinguish between HF and exacerbation of COPD on the one hand and other causes of dyspnea on the other [36].…”

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

“…The authors performed regression and ROC analyses and reported seven miRNAs associated with HF diagnosis (miR-103, AUC 0.642; miR-142-3p, AUC 0.668; miR-199a-3p, AUC 0.668; miR-23a, AUC 0.637; miR-27b, AUC 0.642; miR-324-5p, AUC 0.621; miR-342-3p, AUC 0.644) [36]. Interestingly, from a clinical point of view, plasma levels of four of these miRNAs were suitable to distinguish between HF and exacerbation of COPD on the one hand and other causes of dyspnea on the other [36]. Compared with the previously mentioned studies, miR-423-5p could not be identified to predict HF diagnosis, but in a combinatory approach the addition of miR-423-5p to NT-proBNP led to a significant improvement of the AUC for diagnosing HF [36].…”

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

See 2 more Smart Citations

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

Section: Mirnas As Circulating Diagnostic Biomarkers In Heart Failurementioning

confidence: 99%

See 1 more Smart Citation

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

show abstract

“…In summary, these data suggested that miR-103 may be used to design novel strategies against CRC growth and metastasis in the future. Previous studies have shown that miR-103 is involved in various biological and pathological processes, including glucose homeostasis, insulin sensitivity (21) and heart failure (22). miR-103 has also been reported to associate with several human cancers.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2

Zheng

Xiao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Colorectal cancer (CRC) has become the third most common cancer worldwide and leads to a high mortality rate. Although colorectal cancer has been studied widely, the underlying molecular mechanism remains unclear. Increasing evidence shows that the abnormal expression of microRNAs (miRNAs) is involved in tumorigenesis. Previous studies have reported that miRNA-103 (miR-103) is dysregulated in CRC; however, the expression, function and mechanism of miR-103 in CRC are not well known. The present study showed that miR-103 was overexpressed in the primary tumor tissues of patients with CRC and was significantly associated with a more aggressive phenotype of CRC in patients. Survival rate analysis demonstrated that CRC patients with high miR-103 expression had a poorer overall survival compared with CRC patients with low miR-103 expression. In CRC cell lines, miR-103 inhibition significantly decreased the proliferation, invasion and migration of the cells in vitro. Furthermore, miR-103 repressed large tumor suppressor kinase 2 (LATS2) expression by directly binding to the LATS2-3'-untranslated region, and an inverse correlation was identified between the expression of miR-103 and LATS2 messenger RNA in primary CRC tissues. In addition, the restoration of LATS2 led to suppressed proliferation, invasion and migration of CRC cells. In vivo, miR-103 promotes tumor growth in nude mice. In summary, miR-103 performs a critical role in the promotion of the invasive and metastatic capacities of CRC, possibly by directly targeting LATS2. This miRNA may be involved in the development and progression of CRC.

show abstract

“…73) Ellis, et al investigated the diagnostic utility of miRNAs in differentiating between patients with heart failure and non-heart failure-related breathlessness. 74) Four miRNAs, miR103, miR142-3p, miR30b, and miR342-3p, were differentially expressed between HF and controls, chronic obstructive pulmonary disease, and other breathless patients.…”

Section: Circulating Micrornasmentioning

confidence: 92%

Biomarkers in Heart Failure

Takeishi

2014

Int. Heart J.

View full text Add to dashboard Cite

SummaryAppropriate use of biomarkers is clinically important for identifying heart failure in its early stage, optimizing risk stratification, and managing patients. This article describes established and traditional biomarkers as well as novel biomarkers reflective of myocardial stress, myocardial damage, extracellular matrix, oxidative stress, inflammation, renal function, micro RNAs, and heart failure with preserved left ventricular ejection fraction. This review focuses on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. (Int Heart J 2014; 55: 474-481) Key words: BNP, NT-proBNP, ST2, Troponin, H-FABP, Galectin-3, Cystatin C, Pentraxin 3 C ardiovascular diseases are the predominant cause of death in developed countries. Among the afflicted, patients with heart failure are increasing, and this complex syndrome is becoming a public health problem, especially with the aging of populations. To establish diagnostic, therapeutic, and prognostic strategies, the identification of reliable biomarkers for heart failure is necessary.1,2) Although a number of biomarkers have been developed, the ideal biomarkers should meet certain criteria: 1) non-invasive sample collection, 2) a high degree of sensitivity and specificity, 3) able to detect the disease at an early stage, 4) sensitivity high enough to reflect relevant changes in disease conditions, 5) a long halflife within the sample, 6) rapid measurement system responding to clinical needs, and 7) low cost. 3,4) In this article, the focus will be on the recent advances in cardiac and non-cardiac biomarkers of heart failure and their appropriate use in clinical practice. Myocardial Stress MarkersB-type natriuretic peptide: B-type natriuretic peptide (BNP) is a well-established biomarker, extensively used for the diagnosis and prognosis of patients with heart failure. BNP is a cardiac hormone, identified as the second compound of the natriuretic peptide family and secreted predominantly from the ventricle in response to mechanical overload. 5) In the failing heart, increased wall stress and neurohormonal activation facilitate BNP secretion chiefly from ventricular myocytes. BNP promotes diuresis, vasodilatation, and attenuation of renin and aldosterone secretion. Tsutamoto, et al initially measured plasma levels of BNP in 85 patients with chronic heart failure and a left ventricular ejection fraction (LVEF) of less than 0.45. 6)The plasma levels of BNP increased in proportion to the severity of heart failure. Plasma levels of BNP were 5-fold higher in non-survivors than in survivors. Among clinical and hemodynamic parameters, Cox proportional hazard analysis revealed that only plasma BNP (P < 0.0001) and pulmonary capillary wedge pressure (P = 0.003) were significant independent predictors of mortality in patients with heart failure. Plasma levels of BNP provided prognostic information independent of other variables previously associated with a poor prognosis. To date, a number of studies have r...

show abstract

Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients

Cited by 158 publications

References 39 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

MicroRNA-103 promotes tumor growth and metastasis in colorectal cancer by directly targeting LATS2

Biomarkers in Heart Failure

Contact Info

Product

Resources

About